## CRL: Charles River Laboratories Inte - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_10 at 3.2% in lower entry zone (3.0-6.0%), top quartile (82nd pct) cross-sectional ranking. Short-term MRS_5 (2.1%) confirms momentum alignment. Strong momentum (+3.4% 5-day acceleration). Outperforming sector by 6.6%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($174.32)
- **If Wrong:** Exit if MRS_10 drops below entry zone or breaks stop
- **Invalidation:** MRS_10 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Burgundy Asset Management Ltd. Buys 277,450 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251207T100848 | Somewhat-Bullish | Relevance: 99%
-  Burgundy Asset Management Ltd. significantly increased its stake in Charles River Laboratories International Inc. (NYSE:CRL) by 10,200.4% in the second quarter, now owning 280,170 shares worth approximately $42.51 million. Several other hedge funds also adjusted their positions in the medical research company. CRL's stock performance shows a positive trend with its 50-day moving average above its 200-day moving average, and analysts maintain a "Moderate Buy" rating with an average price target of $190.86.

**2. Edgestream Partners L.P. Invests $1.80 Million in Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251206T130757 | Somewhat-Bullish | Relevance: 99%
-  Edgestream Partners L.P. has acquired a new stake worth approximately $1.80 million in Charles River Laboratories International, Inc. (NYSE:CRL) during the second quarter. Other institutional investors have also adjusted their holdings in the company, which reported strong quarterly earnings exceeding analyst expectations. The stock currently holds a "Moderate Buy" rating with an average price target of $190.86 from analysts.

**3. Charles River Laboratories (CRL): Reassessing Valuation After a Quiet Share Price Rebound**
- Source: Simply Wall Street | 20251207T000806 | Bullish | Relevance: 99%
- Charles River Laboratories (CRL) has seen a quiet share price rebound, up 10% in the past month and 12% in three months, despite a negative 1-year return. The company is considered 2.4% undervalued, with a fair value of $188.93, driven by anticipated recovery in biopharma demand and expanded client R&D pipelines. Investors are reassessing CRL's growth potential and intrinsic value discount, wondering if it presents a compelling entry point.

**4. Invesco Ltd. Purchases 128,785 Shares of Charles River Laboratories International, Inc. $CRL**
- Source: MarketBeat | 20251208T112406 | Bullish | Relevance: 98%
- Invesco Ltd. has increased its stake in Charles River Laboratories International, Inc. by 11.6%, acquiring an additional 128,785 shares to a total of 1,237,143 shares valued at approximately $187.7 million. This move brings Invesco's total ownership to 2.51% of the company. The medical research company recently exceeded quarterly earnings expectations, and analysts have a "Moderate Buy" rating with an average price target of $190.86.

**5. Charles River Laboratories (CRL): Reassessing Valuation After a Quiet Share Price Rebound**
- Source: Simply Wall Street | 20251206T113241 | Bullish | Relevance: 98%
- Charles River Laboratories International (CRL) has seen its stock rebound by 10% in the past month and 12% in three months, despite a negative 1-year return. With modest top-line growth, improved profitability, and shares trading at an intrinsic value discount, the company is considered "Undervalued" at $188.93 compared to its last close of $184.31. This positive outlook is driven by anticipated recovery in biopharma demand and increased healthcare spending, although potential risks from biotech funding stalls or regulatory shifts exist.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-11 | Morgan Stanley | $185 | $170 | +9% |
| 2025-11-10 | TD Cowen | $197 | $205 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-11 | Morgan Stanley | main | Equal-Weight |
| 2025-11-10 | TD Cowen | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 1 ($0.50M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.9% (+0.5%)
- Blackrock Inc.: 7.8% (+5.5%)
- Wellington Managemen: 6.5% (-15.3%)
- Allspring Global Inv: 4.4% (-4.9%)
- State Street Corpora: 3.7% (-1.5%)

### Key Risks

1. Market regime shift could impact high-beta names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_10 improving +3.4% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 17.1x stretched relative to 7% growth. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.64 |
| 52W Range | $91.86 - $202.72 |
| Short Interest | 6.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 17.1 |
| Current P/E | 18.3 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 strengthening from -0.2% to 3.2% (+3.4% in 5 days), confirming momentum buildup. Currently in lower STRENGTH zone (3.0-6.0%), cross-sectional ranking at 82nd percentile. MRS_5 at 2.1% confirms short-term momentum alignment. Outperforming sector by 6.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.90), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 3.19% (CS: 82) | Strong |
| RSI_14 | 65.1 | Neutral |
| MACD Histogram | 1.90 | Bullish |
| vs SMA20 | 1.080x | Above |
| vs SMA50 | 1.070x | Above |
| vs SMA200 | 1.199x | Above |

### Decision

- **Verdict:** BUY
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $187.12
- **Stop Loss:** $174.32 (6.8% risk)
- **Target:** $206.32 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 39
- **Position Value:** $7,297.68
- **Portfolio %:** 7.30%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-18 (Est: $2.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.34 | $2.43 | +3.9% |
| 2025Q2 | $2.55 | $3.12 | +22.4% |
| 2025Q1 | $2.07 | $2.34 | +12.8% |
| 2024Q4 | $2.53 | $2.66 | +5.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*